
Oryzon Genomics announces publication of phase 2a ALICE trial results
Betsy Goodfellow | June 4, 2024 | News story | Medical Communications | AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The Lancet Hematology.
The trial evaluated iadademstat in combination with azacytidine in unfit patients with newly diagnosed acute myeloid leukaemia (AML). A summary of this final data was previously shared in an oral presentation at the 2022 American Society for Hematology (ASH) annual meeting.
The data showed that this combination induced 82% of patients having an objective response, and 52% of patients achieving either a complete remission (CR) or a complete remission with incomplete haematological recovery (CRi). Many of the responses (87%) occurred rapidly, with 36% lasting at least 12 months.
Dr Carlos Buesa, chief executive officer of Oryzon Genomics, commented: “We are thrilled to publish these groundbreaking results in one of the most prestigious journals in clinical oncology. Our study demonstrates that targeting LSD1 is a completely novel anti-leukaemic mechanism of action in AML, potentially offering a new therapeutic approach, especially for patients with hard-to-treat forms of the disease such as myelomonocytic leukaemias, DNMTs mutations or TP53 mutations. These patients currently respond poorly to available treatments and may benefit from the innovative treatment option of iadademstat. We want to reiterate our gratitude to the patients, their families and the researchers involved in this study.”
Betsy Goodfellow
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …





